Medicated gummies represent a significant, patient-centric evolution in oral drug delivery, offering a palatable and easily administered alternative to traditional tablets and capsules. This comprehensive review synthesizes the current scientific literature to evaluate the viability of gummies as a novel oral solid dosage form. The review first highlights the primary advantages, focusing on enhanced patient adherence and acceptability across vulnerable populations, including pediatric, geriatric, and dysphagic patients. A detailed analysis is provided on the critical physicochemical properties of Active Pharmaceutical Ingredients (APIs) that govern their suitability for gummy formulation. Furthermore, the article explores the fundamental formulation science, contrasting key gelling agents like gelatin and pectin, and strategies for modifying drug release kinetics, from immediate to sustained profiles. The core challenges in manufacturing are thoroughly discussed, specifically addressing issues of chemical stability and the necessity of advanced taste-masking technologies. In conclusion, while medicated gummies offer substantial therapeutic benefits and market potential, their successful development hinges on overcoming complex formulation and manufacturing hurdles, positioning them as a rapidly evolving frontier in pharmaceutical technology.
Khadri et al. (Wed,) studied this question.